CAR-T 细胞疗法市场按目标抗原、治疗用途、地区-规模、份额、前景和机会分析2022-2030

CAR-T 细胞疗法是一种利用免疫 T 细胞消灭癌症的免疫疗法。 CAR-T细胞疗法也被称为细胞基因疗法，因为它修饰了T细胞的基因。 CAR-T 细胞疗法使用一种称为白细胞去除术的方法从体内去除 T 细胞。 提取的 T 细胞被称为 CAR-T 细胞，因为它们通过添加特定的嵌合抗原受体 (CAR) 基因进行修饰。 CAR-T 细胞通过引入特定的嵌合抗原受体 (CAR) 基因进行修饰，然后扩增并註射到体内。 各种类型的 CAR-T 细胞疗法旨在对抗某些类型的癌症。 CAR-T细胞是为每位患者定制的，并註入血液中。 CAR-T细胞疗法被用作抗癌的新基因疗法。 各种临床和临床前研究正在进行中，以研究各种 CAR-T 细胞疗法对特定癌症的安全性和有效性。 还有一些政府举措旨在提高人们对癌症的认识，包括美国疾病控制和预防中心 (CDC) 开展的教育活动。

市场动态

市场上的主要参与者越来越多地采用有机策略，例如产品批准，预计这将在预测期内推动市场增长。 例如，2022年5月，全球医疗保健公司诺华公司宣布美国食品和药物管理局批准Kymriah（tisagenlecleucel）CAR-T细胞疗法用于治疗成人復发或难治性滤泡性淋巴瘤患者，并获得批准。 该批准基于对 II 期临床试验中 68% 响应率的评估。

这项研究的主要特点

• 本报告对全球 CAR-T 细胞疗法市场进行了深入分析，显示了以 2021 年为基准年的预测期 (2022-2030) 的市场规模和復合年增长率 (CAGR%)。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供重要的见解，例如市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略。
• 根据公司亮点、产品组合、主要亮点、财务业绩和战略等参数介绍全球 CAR-T 细胞疗法市场主要参与者的概况。
• 本研究涵盖的主要公司包括 Bristol-Myers Squibb Company、Johnson & Johnson Services, Inc.、Novartis AG、CARsgenTherapeutics Co.,Ltd、Aurora Biopharma、Legend Biotech、Gilead Sciences, Inc.、Pfizer Inc. ., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics 等知名企业
• 这份报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 《全球 CAR-T 细胞疗法市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球 CAR-T 细胞疗法市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按目标抗原分类
  • 市场概况：按治疗应用分类
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 市场趋势
• 近期趋势
• 收购和合作场景
• 监管场景
• 管道分析
• 害虫分析
• 搬运工分析

第 4 章 CAR-T 细胞疗法的全球市场 - COVID-19 影响分析

• 总体影响
• 对供需的影响
• COVID-19 对市场的影响

第 5 章全球 CAR-T 细胞疗法市场：按目标抗原分类，2017-2030

• CD19
• BCMA
• HER2
• GD2
• CD20
• CD22
• CD30
• CD33
• HER1
• 其他（CLDN18 等）

第 6 章全球 CAR-T 细胞疗法市场：按治疗用途分类，2017-2030

• 急性淋巴细胞白血病
• 慢性淋巴细胞白血病
• 瀰漫性大 B 细胞淋巴瘤 (DLBCL)
• 滤泡性淋巴瘤
• 套细胞淋巴瘤
• 多发性骨髓瘤
• 胶质母细胞瘤
• 肉瘤
• 神经母细胞瘤
• 急性髓性白血病
• 乳腺癌
• 胰腺癌
• 肝细胞癌
• 结肠癌
• 其他（胃癌等）

第 7 章全球 CAR-T 细胞疗法市场：按地区划分，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第八章竞争格局

• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• CARsgenTherapeutics Co.,Ltd
• Aurora Biopharma
• Legend Biotech
• Gilead Sciences, Inc.
• Pfizer Inc.
• bluebird bio, Inc.
• Sorrento Therapeutics, Inc.
• Mustang Bio
• Fate Therapeutics

第 9 章

• 调查方法
• 关于出版商

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study:

• This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market

Detailed Segmentation:

• Global CAR T Cell Therapy Market, By Targeted Antigen:
  • CD19
  • BCMA
  • HER2
  • GD2
  • CD20
  • CD22
  • CD30
  • CD33
  • HER1
  • Others (CLDN18, etc.)
• Global CAR T Cell Therapy Market, By Therapeutic Application:
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others (Gastric Cancer, etc.)
• Global CAR T Cell Therapy Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • CARsgenTherapeutics Co., Ltd
  • Aurora Biopharma
  • Legend Biotech
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • bluebird bio, Inc.
  • Sorrento Therapeutics, Inc.
  • Mustang Bio
  • Fate Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Targeted Antigen
  • Market Snapshot, By Therapeutic Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis
• Porter's Analysis

4. Global CAR T Cell Therapy Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global CAR T Cell Therapy Market, By Targeted Antigen, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• CD19
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• BCMA
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• GD2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD20
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD22
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD30
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD33
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER1
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (CLDN18, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global CAR T Cell Therapy Market, By Therapeutic Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Acute Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Chronic Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Diffuse Large B-cell Lymphoma (DLBCL)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Follicular Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Mantle Cell Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Multiple Myeloma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Glioblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Sarcoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Neuroblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Acute Myeloid Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hepatocellular Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Gastric Cancer, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global CAR T Cell Therapy Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Johnson & Johnson Services, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CARsgenTherapeutics Co.,Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aurora Biopharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Legend Biotech
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• bluebird bio, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sorrento Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mustang Bio
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fate Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us